Browse institutions

…Zykadia), ramucirumab (Cyramza), and nintedanib (Vargatef); the FDA also granted a claim to ceritinib (Zykadia). Limited HCP-facing…

…r of medicines approved by the following regulatory agencies is FDA (n=84, 55%), EMA (n=80, 52%), MHRA (n=71, 46%), TGA (n=51, 33%)…

… sources from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The framework covers: (i) uniform reporting; (ii) curate…

…rformed by the USA’s National Institutes of Health (NIH) or the National Cancer Institute. In the study of Zhou et al, of all classes of drugs, costs of …

…atest Pharmacovigilance Risk Assessment Committee assessment at EMA requested monitoring requirements for rimegepant be eased from …

…4;JCO 42:7047-7047. DOI:10.1200/JCO.2024.42.16_suppl.70472 U.S. FDA approves Bristol Myers Squibb’s 2. Breyanzi® as the first and o…

…ls. (P8) Lack of institutional protocolsMost institutes, unlike Tata Hospital, don’t have their own protocols. (P7) Robustness and timely upd…